Helicos Biosciences (NASDAQ: [[ticker:HLCS]]), the Cambridge, MA-based maker of genetic analysis instruments, said today in a regulatory filing that president Steve Lombardi has resigned. Lombardi’s exit was official as of February 11 from his full-time job and from his position on the board of directors. Helicos didn’t say why Lombardi is leaving, but noted that it wasn’t because of a disagreement with the company over operations, policies, or practices. Lombardi will continue to earn his salary through August 31, at his annual base rate of $375,000. Lombardi had been CEO of Helicos from August 2008 to December 2008, when he was replaced in the company’s top job by Ronald Lowy.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
